Abstract
Primary chronic venous disease (CVD) is a common condition that can cause significant morbidity for sufferers and considerable burden on health care systems. Prolonged venous hypertension in conjunction with valvular incompetence and venous reflux is responsible for the diverse clinical manifestations of CVD and links all theories regarding CVD pathogenesis. Recent data suggest that valve damage may be acquired rather than congenital, and caused by inflammatory factors, notably leukocyte activation triggered by venous hypertension. Valve incompetence leads to reflux, reinforcing venous pressure elevation and initiating a vicious circle of disease progression. Loss of venous tone and lymphatic overload also play a role. Valve failure in superficial and perforating veins leads to elevated pressure in the veins and venules of the skin and subcutaneous tissue, resulting in skin hyperpigmentation, induration and ultimately ulceration. The inflammatory cascade may be ameliorated by pharmacologic intervention to decrease leukocyte activation and leukocyte endothelial interactions at both macro- and microcirculatory levels. Daflon 500 mg (micronized purified flavonoid fraction) offers great potential for achieving this with demonstrated efficacy in reducing inflammation and thus providing tissue protection at all stages of the disease. Experiments in animal and human models of CVD have shown that Daflon 500 mg modulates leukocyte rolling and adhesion and prevents endothelial damage in both veins and capillaries. Such treatment is useful for first-line management of edema as well as associated symptoms of CVD. A recent meta-analysis has confirmed that venous leg ulcer healing is accelerated by adding Daflon 500 mg to conventional treatment.
Keywords: Chronic venous disease, micronized purified flavonoid fraction, venous hypertension, venous reflux
Current Pharmaceutical Design
Title: Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease
Volume: 13 Issue: 4
Author(s): Luigi Pascarella
Affiliation:
Keywords: Chronic venous disease, micronized purified flavonoid fraction, venous hypertension, venous reflux
Abstract: Primary chronic venous disease (CVD) is a common condition that can cause significant morbidity for sufferers and considerable burden on health care systems. Prolonged venous hypertension in conjunction with valvular incompetence and venous reflux is responsible for the diverse clinical manifestations of CVD and links all theories regarding CVD pathogenesis. Recent data suggest that valve damage may be acquired rather than congenital, and caused by inflammatory factors, notably leukocyte activation triggered by venous hypertension. Valve incompetence leads to reflux, reinforcing venous pressure elevation and initiating a vicious circle of disease progression. Loss of venous tone and lymphatic overload also play a role. Valve failure in superficial and perforating veins leads to elevated pressure in the veins and venules of the skin and subcutaneous tissue, resulting in skin hyperpigmentation, induration and ultimately ulceration. The inflammatory cascade may be ameliorated by pharmacologic intervention to decrease leukocyte activation and leukocyte endothelial interactions at both macro- and microcirculatory levels. Daflon 500 mg (micronized purified flavonoid fraction) offers great potential for achieving this with demonstrated efficacy in reducing inflammation and thus providing tissue protection at all stages of the disease. Experiments in animal and human models of CVD have shown that Daflon 500 mg modulates leukocyte rolling and adhesion and prevents endothelial damage in both veins and capillaries. Such treatment is useful for first-line management of edema as well as associated symptoms of CVD. A recent meta-analysis has confirmed that venous leg ulcer healing is accelerated by adding Daflon 500 mg to conventional treatment.
Export Options
About this article
Cite this article as:
Pascarella Luigi, Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease, Current Pharmaceutical Design 2007; 13 (4) . https://dx.doi.org/10.2174/138161207780162953
DOI https://dx.doi.org/10.2174/138161207780162953 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
Innovative delivery systems and formulations for the management of diseases affecting the skin and skin appendages
Skin and skin appendage diseases have high incidence and can highly impact the quality of life. Such diseases include pigmentation disorders, such as melasma, vitiligo and post-inflammatory hyperpigmentation, infectious diseases caused by fungi, viruses, bacteria and parasites, inflammatory diseases such as acne, dermatitis, rosacea, and psoriasis, as well as skin ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Health Impact and Management of a Disrupted Circadian Rhythm and Sleep in Critical Illnesses)
Current Pharmaceutical Design Onset of Hypertension in Leflunamide Treated Low Socioeconomic Rheumatoid Arthritis Patients: An Unseen Iceberg
Current Rheumatology Reviews Polyphenols: Novel Signaling Pathways
Current Pharmaceutical Design Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Editorial: Impact of Racial Differences on Brain Health among the Oldest Old
Current Alzheimer Research Sarcoidosis in Pregnancy and Postpartum Period
Current Respiratory Medicine Reviews Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Current Pharmaceutical Design Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Adrenomedullin in Hypertension
Current Hypertension Reviews Chemical Constituents and Biological Significance of the Genus Ilex (Aquifoliaceae)
The Natural Products Journal Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II.
Current Diabetes Reviews Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review
Protein & Peptide Letters Stroke Suggests Increased Risk of Dementia
Current Alzheimer Research Orofacial Pain and Mastication in Dementia
Current Alzheimer Research Neuronal Histamine and its Receptors: Implication of the Pharmacological Treatment of Obesity
Current Medicinal Chemistry Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Endothelial Microparticles: Mediators or Markers of Endothelial Cell Dysfunction?
Current Hypertension Reviews Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets